Paladin Labs Inc.  

(Public, TSE:PLB)   Watch this stock  
Find more results for tse: plb
49.45
+0.45 (0.92%)
May 24 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 48.66 - 49.45
52 week 39.01 - 51.89
Open 48.66
Vol / Avg. 8,037.00/12,381.00
Mkt cap 1.02B
P/E 16.82
Div/yield     -
EPS 2.94
Shares 20.57M
Beta 0.38
Inst. own     -
May 9, 2013
Q1 2013 Paladin Labs Inc Earnings Conference Call
Feb 28, 2013
Q4 2012 Paladin Labs Inc Earnings Conference Call
  

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 15.30% 27.76%
Operating margin - 29.43%
EBITD margin - 36.44%
Return on average assets 6.96% 11.64%
Return on average equity - 16.96%
Employees 126 -
Carbon Disclosure Rating - -

Address

Suite 600, 100 Blvd. Alexis Nihon
ST.LAURENT, QC H4M 2P2
Canada
+1-514-3401112 (Phone)
+1-514-3444675 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Paladin Labs Inc. is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. The Company�s product portfolio includes Tridural, Abstral and Trelstar. Tridural is a once-a-day tramadol product indicated as a first-line therapy for adults with moderate pain requiring several days or more of treatment. Abstral is a sublingual tablet used for the management of breakthrough cancer pain in patients who are already tolerant to other opioid analgesics. Trelstar is an injectable, luteinizing hormone releasing hormone agonist indicated for the palliative treatment of prostate cancer and endometriosis. In February 2011, the Company acquired the Tempra line of products in Canada from Bristol-Myers Squibb. In November 2011, it acquired the rights to Travelan in Canada, Latin America and Sub-Saharan Africa. Effective January 1, 2013, the Company acquired Ativa Pharma S.A.

Officers and directors

Jonathan Ross Goodman Chairman of the Board
Age: 45
Mark A. Beaudet Interim President, Interim Chief Executive Officer, Secretary, Director
Samira Sakhia Chief Financial Officer
Michael R. Freeman Vice President - Government Affairs
Patrice Larose Vice President - Regulatory Affairs, Drug Safety and Medical Services
Portrait.
Mark H. Nawacki Vice President - Business and Corporate Development
Ted S. Wise Independent Chairman Emeritus
James C. Gale Lead Independent Director
Age: 63
Robert N. Lande Independent Director
Gerald P. McDole Independent Director
Age: 73